Gilead Company Kite and Sangamo Therapeutics have entered a global collaboration using the latter’s zinc finger nuclease (ZFN) technology platform to develop new ex-vivo cell therapies in oncology.

As part of the collaboration, Sangamo’s gene-editing technology will be used by Kite to modify genes to develop the therapies for use in treating various types of cancers.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Sangamo Therapeutics president and CEO Sandy Macrae said: “This collaboration between Kite and Sangamo brings together two leading platforms to develop best-in-class cell therapies in oncology.

“We are excited by Kite’s commitment to driving innovation in this field and look forward to working together to realise the full promise of cell therapy in treating cancer.”

By collecting allogeneic cell therapies from healthy donor cells or from renewable stem cells a potential treatment option would be available that can be accessed directly within the oncology infusion centre, thereby reducing the time to infusion for patients.

“This collaboration between Kite and Sangamo brings together two leading platforms to develop best-in-class cell therapies in oncology.”

Under the agreement, Sangamo will receive an upfront payment of $150m.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the company is eligible for up to $3.01bn in potential payments, aggregated across ten or more products using its technology, based on the achievement of certain research, development, regulatory and commercialisation milestones.

Kite will develop, manufacture and commercialise products under the collaboration, and will be responsible for agreed upon expenses that would be incurred by Sangamo.

Gilead president and CEO John Milligan said: “The emergence of gene editing as a tool to edit immune cells holds promise in the development of therapies with potentially improved safety, efficacy and efficiency.”

The transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act, as well as other customary closing conditions.